Physician profile
Sohail Ejaz
NPI 1942263678
$5,087.50
in general payments reported to CMS, 2019-2025
25 companies · $794 in 2025
The $794 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $539 · 2020: $250 · 2021: $474 · 2022: $911 · 2023: $1,115 · 2024: $1,003 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,666 · Consulting Fee: $200 · Education: $46.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,666.44 |
| Consulting Fee | $200.00 |
| Education | $46.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $802.29 | 2019-2025 | Tavneos, Krystexxa, Repatha |
| Astrazeneca Pharmaceuticals LP | $667.06 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $633.43 | 2019-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $346.43 | 2019-2024 | Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $291.62 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $287.92 | 2021-2025 | |
| Glaxosmithkline, LLC. | $277.79 | 2023-2024 | Benlysta |
| Horizon Therapeutics Plc | $221.37 | 2019-2023 | Krystexxa |
| Daiichi Sankyo INC. | $217.48 | 2019-2024 | Injectafer |
| Opko Pharmaceuticals, LLC | $178.23 | 2019-2024 | Rayaldee |
| Travere Therapeutics, INC. | $176.11 | 2020-2025 | Thiola |
| Calliditas Therapeutics US INC. | $153.95 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $129.01 | 2021-2025 | |
| Outset Medical INC | $109.54 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.77 | 2024-2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $74.91 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $71.44 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $65.01 | 2019 | |
| Mallinckrodt Hospital Products INC. | $61.06 | 2020 | |
| Aurinia Pharma U.S., INC. | $59.16 | 2024 | Lupkynis |
| Ardelyx, INC. | $52.41 | 2023-2025 | Ibsrela |
| Amag Pharmaceuticals, INC. | $35.66 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $33.88 | 2022-2025 | Amvuttra |
| Alexion Pharmaceuticals, INC. | $32.80 | 2021-2025 | Ultomiris |
| Genzyme Corporation | $17.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Ejaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.